Yona Geffen, Ph.D, Chief Executive Officer Avraham Pharmaceuticals.
The company is developing novel products for treatment and prevention of neurodegenerative disorders. Dr. Geffen Joined Avraham Pharmaceuticals in January 2011 as Vice President of Clinical affairs , In April 2012 Dr. Geffen was appointed as Avraham Pharmaceuticals Chief Executive Officer
Dr. Geffen has more than 15 years of experience in leading drug development in biopharmaceutical companies specialized in the CNS field. Prior to joining Avraham Pharma, she served as an Executive Drug Development Director at BioLineRx (NASDAQ: BLRX), where she managed the development of a drug candidate for the treatment of schizophrenia and cognition. Before that she was involved in developing drugs for ALS, Huntington’s disease and Stroke. Dr. Geffen holds a Ph.D. in Immunology and Microbiology and an M.Sc. in business management, both from the Ben-Gurion University, Israel.